Group 1 - The company, Lisheng Pharmaceutical (002393), responded to investor inquiries on an interactive platform regarding the number of shareholders [1] - The latest number of shareholders will be disclosed in the company's periodic reports, specifically in the "2025 Third Quarter Report" published on October 24, 2025 [1]

Core Viewpoint - The company, Lisheng Pharmaceutical, announced the approval of the proposal to appoint the auditing institution for the fiscal year 2025 during its fourth extraordinary shareholders' meeting [2] Group 1 - The fourth extraordinary shareholders' meeting was held on December 22 [2] - The proposal regarding the appointment of the auditing institution for the year 2025 was approved [2]

证券代码：002393 证券简称：力生制药 公告编号：2025-087 天津力生制药股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决提案的情形。 2.本次股东会未涉及变更以往股东会已通过的决议。 3.本次股东会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议：2025年12月22日（星期一）下午3:30开始 （2）网络投票：2025年12月22日（星期一） 其中通过深圳证券交易所交易系统进行网络投票的具体时间为2025年12月22日上午 9:15—9:25,9:30—11:30和13:00—15:00；通过深圳证券交易所互联网投票系统进行网络 投票的具体时间为2025年12月22日9:15～15:00期间的任意时间。 2．会议召开地点：天津力生制药股份有限公司会议室 天津市西青经济技术开发区赛达北一道16号 3．会议方式：本次股东会采取现场投票与网络投票相结合的方式 4．会议召集人：公司董事会 5．现场会议 ...

天津力生制药股份有限公司2025年第四次临时股东会 之 关于 法律意见书 天津市四方君汇律师事务所 Join & High Law Office 关于天津力生制药股份有限公司 2025 年第四次临时股东会之法律意见书 致：天津力生制药股份有限公司 天津四方君汇律师事务所（以下简称"本所"）接受天津力生制药股份有限公司（以下简 称"公司"）委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范性文件（以下简称 "法律、法规"）以及《天津力生制药股份有限公司章程》（以下简称"《公司章程》"）有 关规定，就公司召开 2025 年第四次临时股东会（以下简称"本次股东会"）有关事宜出具本 法律意见书。 本法律意见书仅就本次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合法律、法规及《公司章程》规定，以及表决结果是否合法有效发表 意见，并不对本次股东会所审议的议案内容以及该等议案所表述的相关事实的真实性、准确性 或合法性发表意见。 为出具本法律意见书，本所律师审查了本次股东会相关的文件、资料，并对本次股 ...

Group 1 - The core viewpoint of the news is that Lisheng Pharmaceutical has shown fluctuations in its financing activities and stock performance, with a notable increase in net profit despite a slight decline in revenue [1][2]. Group 2 - On December 19, Lisheng Pharmaceutical's stock rose by 1.27%, with a trading volume of 52.99 million yuan. The financing buy-in amount was 3.7368 million yuan, while the financing repayment was 5.7458 million yuan, resulting in a net financing buy-in of -2.009 million yuan [1]. - As of December 19, the total balance of margin trading for Lisheng Pharmaceutical was 219 million yuan, which accounts for 4.23% of its circulating market value, indicating a low level compared to the past year [1]. - In terms of short selling, on December 19, Lisheng Pharmaceutical had no shares repaid but sold 1,300 shares, amounting to 26,900 yuan at the closing price. The short selling balance was 82,800 yuan, which is above the 90th percentile of the past year, indicating a high level [1]. Group 3 - As of October 20, the number of shareholders for Lisheng Pharmaceutical was 23,900, an increase of 0.13% from the previous period. The average circulating shares per person decreased by 0.13% to 10,479 shares [2]. - For the period from January to September 2025, Lisheng Pharmaceutical reported a revenue of 1.007 billion yuan, a year-on-year decrease of 1.61%. However, the net profit attributable to the parent company was 371 million yuan, reflecting a significant year-on-year growth of 119.05% [2]. Group 4 - In terms of dividends, Lisheng Pharmaceutical has distributed a total of 1.261 billion yuan since its A-share listing, with 255 million yuan distributed over the past three years [3].

Core Viewpoint - The company aims to enhance research and development alongside industrial synergy, while also advancing ESG management and digitalization to provide better quality medicines for patients and sustainable value returns for investors [1] Group 1 - The company will continue to deepen research and development efforts [1] - The company is committed to advancing ESG (Environmental, Social, and Governance) management [1] - The company focuses on digitalization initiatives [1] Group 2 - The company is dedicated to providing higher quality medicines for patients [1] - The company aims to create sustainable value returns for investors [1]

证券日报网讯12月17日晚间，力生制药（002393）发布公告称，公司副总经理郭晓燕女士于2025年12月 16日至12月17日通过集中竞价方式减持11，200股，占公司剔除回购专用账户股份数量后总股本的 0.0044%，减持计划已实施完成。 ...

一、股东减持基本情况 ■ 二、股东本次减持前后持股情况 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司高级管理人员郭晓燕女士保证向本公司提供的信息内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 天津力生制药股份有限公司（以下简称"公司"）于2025年11月21日在《中国证券报》《证券时报》和巨 潮资讯网（www.cninfo.com.cn）上披露了《关于公司高级管理人员减持股份预披露公告》（公告编 号：2025-075），公司副总经理郭晓燕女士拟自减持计划公告之日起15个交易日后的3个月内以集中竞 价交易的方式合计减持本公司股份数量不超过11,200股，拟减持股份比例不超过公司剔除回购专用账户 中股份数量后总股本的0.0044%。 近日，公司收到郭晓燕女士出具的《关于股份减持计划实施完成的告知函》，现将有关减持计划实施完 成情况公告如下： 2、截至本公告日，郭晓燕女士严格遵守已披露的减持计划，减持实施情况在减持计划范围内，实际减 持股份数量未超过计划减持股份数量。 3、本次减持情况不会导致上市公司控制权发生变更，不会对 ...

Core Viewpoint - The company focuses on the pharmaceutical health industry, implementing a strategic approach of "focusing on core, three forces combined, comprehensive innovation, and win-win cooperation" through the "23456" strategy [1] Group 1: Strategic Focus - The company aims to drive development through a "dual-wheel" approach, enhancing its capabilities by building "three major advantages," establishing "four major sectors," and targeting "five major fields" [1] - The core objective is to achieve a virtuous cycle of "research driving sales, and sales supporting research," ultimately enhancing the company's core competitiveness, industry influence, and international capabilities [1] Group 2: Business Specialization - The company's business focus is reflected in the specialized positioning of its subsidiaries: - The main company serves as the production base for oral solid preparations - Central Pharmaceutical is the production base for soft capsules - Biochemical Pharmaceuticals focuses on sterile preparations - Kunlun Pharmaceuticals is dedicated to active pharmaceutical ingredients - Youth Health Source specializes in traditional Chinese medicine production [1] Group 3: Innovation and Investment - The company emphasizes "comprehensive innovation," leveraging the opportunity of the science and technology reform demonstration to enhance corporate vitality through mechanism, product, technology, marketing, and business model innovations [1] - The company participates in establishing an industrial pharmaceutical fund, focusing on investments in innovative drugs, medical devices, and biotechnology within the health sector, reflecting its "win-win cooperation" strategy [1] - The goal of the fund is to integrate industry resources and provide project reserves and synergistic effects for the long-term development of its main business, rather than shifting focus to cash management [1]

格隆汇12月17日丨力生制药(002393.SZ)公布，近日，公司收到郭晓燕女士出具的《关于股份减持计划 实施完成的告知函》，公司副总经理郭晓燕女士于2025年12月16日-2025年12月17日以集中竞价交易的 方式合计减持本公司股份数量1.12万股，占公司剔除回购专用账户中股份数量后总股本的0.0044%。 ...